Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Apr 1;98(4):550-556.
doi: 10.1097/TA.0000000000004557. Epub 2025 Feb 17.

Predictive value of platelet function assays in traumatic brain injury patients on antiplatelet therapy

Nijmeh Alsaadi  1 , Reem Younes, Jack R Killinger, Lara Hoteit, Ava M Puccio, Peyton McIntyre, Olivia Raymond, Amanda Filicky, Thomas Hahner, Allison G Agnone, Laura E Vincent, Amudan Srinivasan, Mohammadreza Zarisfi, Devin M Dishong, Abiha Abdullah, Aishwarrya Arivudainambi, Ronit Kar, Emily P Mihalko, Patricia Loughran, Stephen R Wisniewski, James F Luther, Philip C Spinella, David Okonkwo, Francis X Guyette, Jason L Sperry, Susan M Shea, Matthew D Neal
Affiliations
Randomized Controlled Trial

Predictive value of platelet function assays in traumatic brain injury patients on antiplatelet therapy

Nijmeh Alsaadi et al. J Trauma Acute Care Surg. .

Abstract

Introduction: Traumatic brain injury (TBI) patients on antiplatelet therapy face higher mortality because of impaired platelet function, which may be treated by platelet transfusion. The value of testing platelet function in this cohort remains controversial. We aimed to evaluate the relationship between platelet function assays and outcomes in TBI patients on antiplatelet therapy receiving platelet transfusions. We hypothesized that the magnitude of change in platelet assay performance following a transfusion would predict meaningful clinical outcomes.

Methods: A cohort of patients, aged 18 to 89 years, with a history of preinjury antiplatelet therapy or who required platelet transfusion, and who were deemed at risk for neurosurgical intervention, was selected from a prospective randomized controlled trial of platelet transfusion for TBI. Pre- and posttransfusion blood samples were drawn. Platelet hemostatic function assays (PHFAs) included thromboelastography with platelet mapping (TEG-PM) and VerifyNow. Logistic regression models assessed the association of temporal assay results with 30-day all-cause mortality, need for craniotomy, and initial and follow-up Rotterdam scores.

Results: Data from 94 TBI patients (43% female) with a median age of 76 years were analyzed. The 30-day mortality rate was 14%. VerifyNow aspirin assay was able to capture increases in platelet function following a platelet transfusion in patients on aspirin (significant positive Δ = 65 aspirin response units, p < 0.001). Thromboelastography with platelet mapping parameters detected improved platelet function following transfusion, although the absolute value of changes was minimal. Thromboelastography with platelet mapping parameters predicted important clinical outcomes on logistic regression, although no significant associations with clinical outcomes were identified by the change in PHFA after transfusion or after adjusting for multiple comparisons.

Conclusion: Higher absolute pre- and posttransfusion values of TEG-PM were associated with decreased mortality, decreased need for neurosurgical intervention, and decreased risk of progression of hemorrhage in TBI patients taking antiplatelet agents, although neither the change in TEG-PM after transfusion nor any other PHFA value predicted outcomes.

Level of evidence: Prognostic and Epidemiological; Level II.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: JTACS COI Disclosure forms for all authors have been supplied and are provided as supplemental digital content.

References

    1. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018;130(4):1080–97. - PubMed
    1. Roozenbeek B, Maas AI, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol. 2013;9(4):231–6. - PubMed
    1. Peterson BA, Thomas KE, Zhou H. Surveillance Report of Traumatic Brain Injury-related Deaths by Age Group, Sex, and Mechanism of Injury—United States, 2018 and 2019.. Centers for Disease Control and Prevention; 2022.
    1. Maegele M, Schochl H, Menovsky T, Marechal H, Marklund N, Buki A, et al. Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management. Lancet Neurol. 2017;16(8):630–47. - PubMed
    1. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. - PMC - PubMed

Publication types

Substances